siRNA takes a jab at hypertension

Hypertension is a modifiable risk factor for cardiovascular disease, the leading cause of death worldwide, yet most US adults with hypertension do not meet goal blood pressure. KARDIA-1 demonstrates the efficacy of zilebesiran, a subcutaneously administered small interfering RNA, for lowering blood pressure, presenting a novel treatment option for this deadly disease. 1 Bakris G.L. Saxena M. Gupta A. Chalhoub F. Lee J. Stiglitz D. Makarova N. Goyal N. Guo W. Zappe D. et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024; 331: 740-749https://doi.org/10.1001/jama.2024.0728 Crossref Scopus (4) Google Scholar Hypertension is a modifiable risk factor for cardiovascular disease, the leading cause of death worldwide, yet most US adults with hypertension do not meet goal blood pressure. KARDIA-1 demonstrates the efficacy of zilebesiran, a subcutaneously administered small interfering RNA, for lowering blood pressure, presenting a novel treatment option for this deadly disease. 1 Bakris G.L. Saxena M. Gupta A. Chalhoub F. Lee J. Stiglitz D. Makarova N. Goyal N. Guo W. Zappe D. et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024; 331: 740-749https://doi.org/10.1001/jama.2024.0728 Crossref Scopus (4) Google Scholar